Volume 4.31 | Aug 16

Prostate Cell News 4.31 August 16, 2013
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Pharmacological Inhibition of Jak2-Stat5 Signaling by Jak2 Inhibitor AZD1480 Potently Suppresses Growth of Both Primary and Castrate-Resistant Prostate Cancer
Efficacy of AZD1480 in disrupting Jak2-Stat5a/b signaling and decreasing prostate cancer (PC) cell viability was evaluated in PC cells. AZD1480 robustly inhibited Stat5a/b phosphorylation, dimerization, nuclear translocation, DNA binding and transcriptional activity in PC cells. [Clin Cancer Res] Abstract
[Free Webinar] A Guide To Successful Flow Cytometry Analysis of ALDHbr Cells - Watch Now.
PUBLICATIONS (Ranked by impact factor of the journal)

Polymerase I and Transcript Release Factor/Cavin-1 Neutralizes Non-Caveolar Caveolin-1 Microdomains in Prostate Cancer
Utilizing PC-3 cells as a suitable model for caveolin-1-positive advanced prostate cancer, scientists found that cavin-1 expression in PC-3 cells inhibits anchorage-independent growth, and reduces in vivo tumor growth and metastasis in an orthotopic prostate cancer xenograft mouse model. [Oncogene] Abstract

Marchantin M: A Novel Inhibitor of Proteasome Induces Autophagic Cell Death in Prostate Cancer Cells
Scientists demonstrated that marchantin M potently inhibited chymotrypsin-like and peptidyl-glutamyl peptide-hydrolyzing activities of 20S proteasome both in in vitro and intracellular systems and significantly induced the accumulation of polyubiquitinated proteins in prostate cancer cells. [Cell Death Dis] Full Article

Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
Scientists report that VPC-3033 exhibited significant activity against prostate cancer cells that have already developed resistance to the second-generation antiandrogen Enzalutamide. [Mol Cancer Ther] Abstract

Cyclin-Dependent Kinase 5 Modulates STAT3 and Androgen Receptor Activation through Phosphorylation of Ser727 on STAT3 in Prostate Cancer Cells
Investigators showed that cyclin-dependent kinase 5 (Cdk5) biochemically interacts with STAT3 and this interaction depends on Cdk5 activation in prostate cancer cells. [Am J Physiol Endocrinol Metab] Abstract

Differential Effects of Thapsigargin Analogues on Apoptosis of Prostate Cancer Cells: Complex Regulation by Intracellular Calcium
Researchers evaluated on LNCaP androgen sensitive cancer cells the effect of thapsigargin substituted with 12-aminododecanoyl linkers and Leu, aspartate, or Boc-8ADT. [FEBS J] Abstract

Activation of FGF2-FGFR Signaling in the Castrated Mouse Prostate Stimulates the Proliferation of Basal Epithelial Cells
In organ culture experiments, basal epithelial proliferation was recapitulated in the absence of DHT. The proliferation of basal epithelial cells in the absence of DHT was suppressed by treatment with an FGF receptor inhibitor. [Biol Reprod] Abstract

Hypoxia Preconditioning of Mesenchymal Stromal Cells Enhances PC3 Cell Lymphatic Metastasis Accompanied by VEGFR-3/CCR7 Signaling Activation
Researchers investigated prostate cancer PC3 cell behavior under the influence of hypoxia preconditioned mesenchymal stromal cells and explored the related mechanism of prostate cancer lymphatic metastases in mice. [J Cell Biochem] Abstract

Piperine Inhibits the Proliferation of Human Prostate Cancer Cells via Induction of Cell Cycle Arrest and Autophagy
Researchers investigated the growth inhibitory effects of piperine on human prostate cancer DU145, PC-3 and LNCaP cells. Although piperine induced low levels of apoptosis, it promoted autophagy as evidenced by the increased level of LC3B-II and the formation of LC3B puncta in LNCaP and PC-3 cells. [Food Chem Toxicol] Abstract


Long-Term Survival of Participants in the Prostate Cancer Prevention Trial
In the Prostate Cancer Prevention Trial, finasteride significantly reduced the risk of prostate cancer but was associated with an increased risk of high-grade disease. With up to 18 years of follow-up, the authors analyzed rates of survival among all study participants and among those with prostate cancer. [N Engl J Med]
Abstract | Press Release

Metastasis-Free Survival Is Associated with Overall Survival in Men with PSA-Recurrent Prostate Cancer Treated with Deferred Androgen Deprivation Therapy
This is a retrospective analysis of 450 men with biochemically recurrent prostate cancer (BRPC) following prostatectomy treated at a single institution between 1981 and 2010, of which 140 developed subsequent metastases. Median metastasis-free survival emerged as an independent predictor of overall survival in men with BRPC treated with deferred androgen deprivation therapy after the development of metastases. [Ann Oncol] Abstract

Learn More: Column-Free Enrichment of Mouse Mammary Stem & Progenitor Cells
Caveola-Forming Proteins Caveolin-1 and PTRF in Prostate Cancer
Evaluation of caveolin-1 antibodies in the clinical setting is underway and it is hoped that future studies will reveal the mechanisms of polymerase I and transcript release factor (PTRF) action, allowing its targeting for therapeutic purposes. [Nat Rev Urol] Abstract

Visit our REVIEWS page to see a complete list of reviews in the prostate cell research field.
Stem Cell Therapeutics Acquires an Exclusive Option to License Prostate Cancer Stem Cell Assets
Stem Cell Therapeutics Corp. announced that it has entered into an option agreement to exclusively license worldwide rights to a series of prostate cancer stem cell assets from the University of York, United Kingdom. [Stem Cell Therapeutics Corp.] Press Release

NxThera Announces Series C Financing & CE Mark
NxThera, Inc. announced an initial closing on its Series C financing of $18.2 million, and receipt of CE Mark for its Rezum® System to treat benign prostatic hyperplasia (BPH). NxThera will use this Series C capital to conduct a U.S. clinical trial to seek FDA clearance to market its Rezum System to treat BPH. [NxThera, Inc.] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUORTM can help.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 2nd Annual Emirates Urological Society Conference 2013
November 14-16, 2013
Abu-Dhabi, United Arab Emirates

Visit our events page to see a complete list of events in the prostate cell community.
NEW Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

NEW Postdoctoral Fellow – Prostate Cancer Research (Mount Sinai School of Medicine)

Research Associate II – Anti-Cancer Agents for the Treatment of Prostate Cancer (Johnson & Johnson)

Postdoctoral Position – Prostate Cancer (Tulane University)

Tenure-Track Position – Cell Biologist (McGill University)

Postdoctoral Fellow – Steroid Receptor Signaling (Baylor College of Medicine)

Faculty Position – Detection and Diagnosis of Solid Tumors (Stanford University)

Lead Research Technologist – Translational Prostate Cancer Research Program (Cleveland Clinic)

Project Scientist – Prostate Cancer Research (University of California at Los Angeles)

Director of Cell Processing Facility (S L Collins Associates, Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Prostate Cell News: Archives | Events | Contact Us